Viking Therapeutics (VKTX) Amortization of Deferred Charges (2019 - 2022)

Viking Therapeutics has reported Amortization of Deferred Charges for 6 years, with the latest figure at $157000.0 in Q2 2026.

• Quarterly Amortization of Deferred Charges rose 40.18% year-over-year to $157000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $450000.0 (up 7.14% YoY) and the FY2025 annual result came in at $431000.0, up 24.57% from the prior year.
• Amortization of Deferred Charges grew to $157000.0 in Q2 2026 per VKTX's latest filing, from $85000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $157000.0 in Q2 2026 and troughed at $72000.0 in Q4 2022.
• A 5-year average of $94235.3 and a median of $85000.0 in 2026 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2022 and 2023: Amortization of Deferred Charges jumped 89.33% in 2022, then plunged 48.59% in 2023.
• Over 5 years, Amortization of Deferred Charges stood at $72000.0 in 2022, then increased by 2.78% to $74000.0 in 2023, then surged by 48.65% to $110000.0 in 2024, then retreated by 14.55% to $94000.0 in 2025, then surged by 67.02% to $157000.0 in 2026.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $157000.0, $85000.0, and $94000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.